{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T06:34:52Z","timestamp":1725518092329},"reference-count":0,"publisher":"Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy","issue":"1","license":[{"start":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T00:00:00Z","timestamp":1645920000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mediterr J Hematol Infect Dis"],"abstract":"<jats:p>Since the emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) at the end of 2019, a number of medications have been used to treat the infection and the related Coronavirus disease \u2013 19 (COVID-19).\nSome of the administered drugs were tested or used in practice only on the basis of biological plausibility; a promising strategy was to target the host immune response, with host directed therapies (HDTs), to reduce systemic hyperinflammation and hypercytokinemia responsible for additional tissue damage.\nWe summarize the treatments against SARS-CoV-2 and underline their possible effects on Mycobacterium tuberculosis (Mtb) infection. Both SARS-CoV-2 and Mtb respiratory infections impair the host\u2019s immune response. Furthermore, little research has been conducted on the impact of medicaments used to counteract COVID-19 disease in patients with Latent Tuberculosis Infection (LTBI). A number of these drugs may modulate host immune response by modifying LTBI dynamic equilibrium, favoring either the host or the bacteria.\n\u00a0\nKeywords: SARS-CoV-2, Mycobacterium tuberculosis, COVID-19, Tuberculosis, Host directed therapies<\/jats:p>","DOI":"10.4084\/mjhid.2022.021","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T08:07:39Z","timestamp":1646035659000},"page":"e2022021","source":"Crossref","is-referenced-by-count":7,"title":["THE DARK SIDE OF THE COVID-19 TREATMENTS ON MYCOBACTERIUM TUBERCULOSIS INFECTION"],"prefix":"10.4084","volume":"14","author":[{"given":"Flavio","family":"De Maio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delia Mercedes","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Delogu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2554","published-online":{"date-parts":[[2022,2,27]]},"container-title":["Mediterranean Journal of Hematology and Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/www.mjhid.org\/index.php\/mjhid\/article\/download\/4772\/4138","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.mjhid.org\/index.php\/mjhid\/article\/download\/4772\/4145","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.mjhid.org\/index.php\/mjhid\/article\/download\/4772\/4138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T08:08:00Z","timestamp":1646035680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mjhid.org\/index.php\/mjhid\/article\/view\/4772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,27]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.4084\/mjhid.2022.021","relation":{},"ISSN":["2035-3006"],"issn-type":[{"value":"2035-3006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,27]]}}}